Yin You

1.6k total citations
34 papers, 1.2k citations indexed

About

Yin You is a scholar working on Immunology, Dermatology and Pediatrics, Perinatology and Child Health. According to data from OpenAlex, Yin You has authored 34 papers receiving a total of 1.2k indexed citations (citations by other indexed papers that have themselves been cited), including 31 papers in Immunology, 15 papers in Dermatology and 8 papers in Pediatrics, Perinatology and Child Health. Recurrent topics in Yin You's work include Psoriasis: Treatment and Pathogenesis (31 papers), Dermatology and Skin Diseases (15 papers) and Pharmaceutical studies and practices (8 papers). Yin You is often cited by papers focused on Psoriasis: Treatment and Pathogenesis (31 papers), Dermatology and Skin Diseases (15 papers) and Pharmaceutical studies and practices (8 papers). Yin You collaborates with scholars based in United States, Canada and United Kingdom. Yin You's co-authors include Kristian Reich, Michael Song, Mark Lebwohl, Yaung‐Kaung Shen, Yves Poulin, Richard G. Langley, Peter Foley, Wayne Langholff, Kavitha Goyal and Steven Fakharzadeh and has published in prestigious journals such as Annals of the Rheumatic Diseases, Journal of the American Academy of Dermatology and British Journal of Dermatology.

In The Last Decade

Yin You

34 papers receiving 1.2k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Yin You United States	17	1.0k	478	341	216	132	34	1.2k
Luke Peterson United States	15	970 1.0×	477 1.0×	480 1.4×	294 1.4×	175 1.3×	59	1.3k
Kavitha Goyal United States	12	828 0.8×	389 0.8×	204 0.6×	118 0.5×	130 1.0×	22	1.0k
Talia M. Muram United States	11	775 0.8×	426 0.9×	206 0.6×	116 0.5×	133 1.0×	18	972
R. You Switzerland	11	1.2k 1.2×	812 1.7×	235 0.7×	174 0.8×	274 2.1×	17	1.3k
R.J.B. Driessen Netherlands	21	760 0.8×	522 1.1×	186 0.5×	95 0.4×	104 0.8×	40	1.0k
P. de la Cueva Spain	22	904 0.9×	554 1.2×	188 0.6×	84 0.4×	124 0.9×	107	1.2k
Zenas Z N Yiu United Kingdom	21	1.2k 1.2×	898 1.9×	308 0.9×	127 0.6×	198 1.5×	72	1.8k
Marco Galluzzo Italy	22	1.0k 1.0×	720 1.5×	212 0.6×	126 0.6×	207 1.6×	86	1.4k
M. Lahfa France	15	933 0.9×	1.1k 2.2×	235 0.7×	148 0.7×	204 1.5×	22	1.6k
H. Bachelez France	16	1.2k 1.2×	822 1.7×	209 0.6×	103 0.5×	270 2.0×	41	1.4k

Countries citing papers authored by Yin You

Since Specialization

Citations

This map shows the geographic impact of Yin You's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Yin You with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Yin You more than expected).

Fields of papers citing papers by Yin You

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Yin You. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Yin You. The network helps show where Yin You may publish in the future.

Co-authorship network of co-authors of Yin You

This figure shows the co-authorship network connecting the top 25 collaborators of Yin You. A scholar is included among the top collaborators of Yin You based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Yin You. Yin You is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Blauvelt, Andrew, Diamant Thaçi, Kim Papp, et al.. (2023). Safety of guselkumab in patients with psoriasis with a history of malignancy: 5-year results from the VOYAGE 1 and VOYAGE 2 trials. British Journal of Dermatology. 189(1). 132–134. 8 indexed citations

Blauvelt, Andrew, Mark Lebwohl, Richard G. Langley, et al.. (2023). Malignancy rates through 5 years of follow-up in patients with moderate-to-severe psoriasis treated with guselkumab: Pooled results from the VOYAGE 1 and VOYAGE 2 trials. Journal of the American Academy of Dermatology. 89(2). 274–282. 12 indexed citations

Reich, Kristian, Kenneth B. Gordon, Bruce Strober, et al.. (2022). Super‐response to guselkumab treatment in patients with moderate‐to‐severe psoriasis: age, body weight, baseline Psoriasis Area and Severity Index, and baseline Investigator's Global Assessment scores predict complete skin clearance. Journal of the European Academy of Dermatology and Venereology. 36(12). 2393–2400. 20 indexed citations

Blauvelt, Andrew, April W. Armstrong, Richard G. Langley, et al.. (2021). Efficacy of guselkumab versus secukinumab in subpopulations of patients with moderate-to-severe plaque psoriasis: results from the ECLIPSE study. Journal of Dermatological Treatment. 33(4). 2317–2324. 21 indexed citations

Blauvelt, Andrew, Tsen‐Fang Tsai, Richard G. Langley, et al.. (2021). Consistent safety profile with up to 5 years of continuous treatment with guselkumab: Pooled analyses from the phase 3 VOYAGE 1 and VOYAGE 2 trials of patients with moderate-to-severe psoriasis. Journal of the American Academy of Dermatology. 86(4). 827–834. 43 indexed citations

Griffiths, C.E.M., Kim Papp, Michael Song, et al.. (2020). Continuous treatment with guselkumab maintains clinical responses through 4 years in patients with moderate-to-severe psoriasis: results from VOYAGE 1. Journal of Dermatological Treatment. 33(2). 848–856. 32 indexed citations

Reich, Kristian, April W. Armstrong, Peter Foley, et al.. (2020). Maintenance of Response Through up to 4 Years of Continuous Guselkumab Treatment of Psoriasis in the VOYAGE 2 Phase 3 Study. American Journal of Clinical Dermatology. 21(6). 881–890. 27 indexed citations

Helliwell, Philip, Dafna D. Gladman, Soumya D. Chakravarty, et al.. (2020). Effects of ustekinumab on spondylitis-associated endpoints in TNFi-naïve active psoriatic arthritis patients with physician-reported spondylitis: pooled results from two phase 3, randomised, controlled trials. RMD Open. 6(1). e001149–e001149. 39 indexed citations

Reich, Kristian, Bruce Strober, Richard G. Langley, et al.. (2020). 15280 Characterization of super responders to guselkumab treatment in moderate to severe psoriasis: Results from the VOYAGE 1 and 2 clinical trials. Journal of the American Academy of Dermatology. 83(6). AB145–AB145. 2 indexed citations

10.

McInnes, Iain B., L. Puig, Alice B. Gottlieb, et al.. (2019). Association Between Enthesitis and Health-related Quality of Life in Psoriatic Arthritis in Biologic-naive Patients from 2 Phase III Ustekinumab Trials. The Journal of Rheumatology. 46(11). 1458–1461. 9 indexed citations

11.

McInnes, Iain B., Soumya D. Chakravarty, Shelly Kafka, et al.. (2019). Efficacy of ustekinumab in biologic-naïve patients with psoriatic arthritis by prior treatment exposure and disease duration: data from PSUMMIT 1 and PSUMMIT 2. RMD Open. 5(2). e000990–e000990. 17 indexed citations

12.

Gordon, Kenneth B., Chenglong Han, Shu Li, et al.. (2019). Correlation of Physician-Assessed Psoriasis Area and Severity Index Scores With Patient-Reported Psoriasis Symptoms and Signs Diary Scores Among Patients With Moderate-to-Severe Psoriasis: Results From VOYAGE 1 and VOYAGE 2 Studies. 4(3). 147–152. 4 indexed citations

13.

Gordon, Kenneth B., April W. Armstrong, Chenglong Han, et al.. (2018). Anxiety and depression in patients with moderate‐to‐severe psoriasis and comparison of change from baseline after treatment with guselkumab vs. adalimumab: results from the Phase 3 VOYAGE 2 study. Journal of the European Academy of Dermatology and Venereology. 32(11). 1940–1949. 60 indexed citations

14.

Armstrong, April W., Kristian Reich, Peter Foley, et al.. (2018). Improvement in Patient-Reported Outcomes (Dermatology Life Quality Index and the Psoriasis Symptoms and Signs Diary) with Guselkumab in Moderate-to-Severe Plaque Psoriasis: Results from the Phase III VOYAGE 1 and VOYAGE 2 Studies. American Journal of Clinical Dermatology. 20(1). 155–164. 34 indexed citations

15.

Strober, Bruce, Robert Bissonnette, David Fiorentino, et al.. (2016). Comparative effectiveness of biologic agents for the treatment of psoriasis in a real-world setting: Results from a large, prospective, observational study (Psoriasis Longitudinal Assessment and Registry [PSOLAR]). Journal of the American Academy of Dermatology. 74(5). 851–861.e4. 63 indexed citations

16.

Kavanaugh, Arthur, L. Puig, Alice B. Gottlieb, et al.. (2016). Efficacy and safety of ustekinumab in psoriatic arthritis patients with peripheral arthritis and physician-reported spondylitis: post-hoc analyses from two phase III, multicentre, double-blind, placebo-controlled studies (PSUMMIT-1/PSUMMIT-2). Annals of the Rheumatic Diseases. 75(11). 1984–1988. 126 indexed citations

17.

Kavanaugh, Arthur, L. Puig, Alice B. Gottlieb, et al.. (2015). SAT0563 Long Term Improvements in Physical Function are Associated with Improvements in Dactylitis, Enthesitis, Tender and Swollen Joint Counts, and Psoriasis Skin Involvement: Results from a Phase 3 Study of Ustekinumab in Psoriatic Arthritis Patients. Annals of the Rheumatic Diseases. 74. 864–864. 2 indexed citations

18.

Kavanaugh, Arthur, L. Puig, Alice B. Gottlieb, et al.. (2015). OP0174 Efficacy and Safety of Ustekinumab in Psoriatic Arthritis Patients with Spondylitis and Peripheral Joint Involvement: Results from a Phase 3, Multicenter, Double-Blind, Placebo-Controlled Study. Annals of the Rheumatic Diseases. 74. 136–136. 3 indexed citations

19.

Kalb, Robert E., David Fiorentino, Mark Lebwohl, et al.. (2015). Risk of Serious Infection With Biologic and Systemic Treatment of Psoriasis. JAMA Dermatology. 151(9). 961–961. 266 indexed citations

20.

Kimball, Alexa B., Philippe Szapary, Ulrich Mrowietz, et al.. (2011). Underdiagnosis and undertreatment of cardiovascular risk factors in patients with moderate to severe psoriasis. Journal of the American Academy of Dermatology. 67(1). 76–85. 103 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact